Cyclerion Therapeutics Reports $3.2 Million Net Loss in Q1 2026, Plans Merger with Korsana Biosciences

Cyclerion Therapeutics, Inc. reported a net loss of $3.2 million for the first quarter of 2026, a significant increase from the $1.4 million loss recorded in the same period of the previous year. The company's total revenues for the quarter were $0, down from $81,000 in the first quarter of 2025, primarily due to the termination of an option agreement related to its olinciguat product. Total expenses rose to $3.2 million, up from $1.5 million in the prior year, driven by increased research and development costs, which surged to $730,000 from $36,000, and general and administrative expenses, which increased to $2.5 million from $1.5 million.

In terms of financial position, Cyclerion's cash and cash equivalents decreased to $2.8 million as of March 31, 2026, down from $3.2 million at the end of 2025. The company’s total assets also fell to $8.5 million from $10 million, while total liabilities increased to $1.7 million from $900,000. The accumulated deficit grew to $274.2 million, reflecting ongoing operational losses. The company has one employee and relies on consultants for its operations, indicating a lean operational structure.

Strategically, Cyclerion is in the process of merging with Korsana Biosciences, a transaction expected to close in the third quarter of 2026, subject to shareholder approval and other conditions. This merger is anticipated to shift Cyclerion's focus towards Korsana's neurodegenerative disease therapies, which will become the primary business of the combined entity. The merger is part of Cyclerion's broader strategy to enhance its product pipeline and address significant unmet medical needs in neuropsychiatric disorders.

Operationally, Cyclerion has made significant strides in its research initiatives, particularly in treatment-resistant depression (TRD), which it has prioritized as a foundational development program. The company entered into a license agreement with the Massachusetts Institute of Technology (MIT) in September 2025 to support its TRD program and a collaboration agreement with Medsteer SAS in January 2026 to leverage technology for anesthetic delivery. However, the company has indicated that it may need to secure additional funding to sustain operations beyond the anticipated merger, as it expects to continue incurring losses.

Looking ahead, Cyclerion's management has expressed substantial doubt about its ability to continue as a going concern without additional funding. The company anticipates that its current cash reserves will only support operations until the merger is completed. If the merger does not proceed, Cyclerion will need to explore alternative funding sources to maintain its operations and continue developing its product candidates.